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Abstract
AIM: To study the clinical efficacy and safety of Fecal 
microbiota transplantation (FMT). We systematically 
reviewed FMT used as clinical therapy. 
METHODS: We searched MEDLINE, EMBASE, the 
Cochrane Library and Conference proceedings from 
inception to July, 2013. Treatment effect of FMT was 
calculated as the percentage of patients who achieved 
clinical improvement per patient category, on an 
intention-to-treat basis. 
RESULTS: We included 45 studies; 34 on Clostridium 
difficile -infection (CDI), 7 on inflammatory bowel 
disease, 1 on metabolic syndrome, 1 on constipation, 
1 on pouchitis and 1 on irritable bowel syndrome 
(IBS). In CDI 90% resolution of diarrhea in 33 case 
series (n  = 867) was reported, and 94% resolution 
of diarrhea after repeated FMT in a randomized 
controlled trial (RCT) (n  = 16). In ulcerative colitis 
(UC) remission rates of 0% to 68% were found (n  = 
106). In Crohn’s disease (CD) (n  = 6), no benefit was 
observed. In IBS, 70% improvement of symptoms 
was found (n  = 13). 100% Reversal of symptoms was 
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observed in constipation (n  = 3). In pouchitis, none 
of the patients (n  = 8) achieved remission. One RCT 
showed significant improvement of insulin sensitivity in 
metabolic syndrome (n  = 10). Serious adverse events 
were rare.
CONCLUSION: FMT is highly effective in CDI, and holds 
promise in UC. As for CD, chronic constipation, pouchitis 
and IBS data are too limited to draw conclusions. FMT 
increases insulin sensitivity in metabolic syndrome. 
Key words: Fecal microbiota transplantation; Microbiota; 
Clostridium difficile  infection; Inflammatory bowel 
disease; Metabolic syndrome
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: Aberrancies in the host’s microbiota have 
been found in several diseases. The most radical way 
to modulate the microbiota is by fecal microbiota 
transplantation (FMT). FMT is already used for various 
diseases while evidence from randomized studies is 
only just emerging. We systematically reviewed the 
efficacy of FMT in Clostridium difficile  infection (CDI), 
inflammatory bowel disease, constipation, irritable 
bowel syndrome, pouchitis, and metabolic syndrome. 
FMT could be incorporated in clinical practice for CDI; 
patients with other indications should currently only be 
treated in clinical trials. Upcoming randomized studies 
on the long-term efficacy and safety of FMT will be 
helpful in the implication of FMT in clinical practice.
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INTRODUCTION
Interest is growing rapidly worldwide for fecal 
microbiota transplantation (FMT) as a ‘‘natural’’ therapy 
from both patients’- and physicians’ perspective. FMT 
is popular among some patients because it is not 
associated with adverse effects from regular medicinal 
therapy. Apart from offering a potentially efficacious 
therapy, FMT provides an ideal human model to study 
the influence of modulating the microbiota in various 
(pre-)disease states. The oldest account of FMT dates 
back to the 4th century, when a Chinese physician 
named Ge Hong produced a paper, in which he advised 
to consume fresh stool from a healthy neighbour when 
suffering from severe diarrhea[1]. The first report in the 
medical literature concerned four patients who were 
successfully treated with FMT for pseudomembranous 
colitis in 1958[2]. Since that time several case series 
on FMT have been published mainly on refractory and 
recurrent Clostridium difficile infection (CDI), but also 
for other intestinal diseases such as ulcerative colitis 
(UC) and irritable bowel syndrome (IBS)[3-6]. From the 
1990’s FMT has been reported in chronic constipation, 
Crohn’s disease (CD), pouchitis, metabolic syndrome, 
chronic fatigue syndrome, idiopathic thrombocytopenic 
purpura and even in multiple sclerosis[7-13]. 
By performing a systematic review we aimed to 
provide a comprehensive assessment of the efficacy 
and safety of fecal microbiota transplantation used as 
clinical therapy for various diseases and pre-clinical 
conditions. Clinical efficacy of FMT was presented per 
indication. In addition, we described safety data, route 
of administration and criteria used for selection and 
screening of donors. 
MATERIALS AND METHODS
This study was executed according to 27 items included 
in The PRISMA statement for reporting systematic 
reviews[14]. All available articles in the English language 
on clinical efficacy and safety of FMT used as clinical 
therapy in human subjects were included in this 
systematic review. These studies included randomized 
controlled trials (RCTs) that compared FMT with 
standard medical therapy or other active comparators, 
placebo or no intervention. Observational studies 
including case-control, cohort studies and case-series 
(number of patients treated greater than one) were also 
included. The search was not restricted to disease type, 
pre-clinical condition, year of publication, publication 
status or length of follow-up (FU). FMT was defined as 
administration of a suspension of donor feces (either 
fresh or frozen) into the gastrointestinal tract. If an 
unclear definition of treatment was given, studies were 
not included; bacteriotherapy with a suspension of 
specific bacterial groups was not regarded as FMT. This 
systematic review was not registered a priori nor was 
a protocol published prior to the start of the study. In 
the nature of this study, no request was performed for 
ethics committee approval.
Outcome measures
Efficacy of FMT was assessed by clinical improvement 
as defined by the authors in the included studies. 
Clinical improvement was defined as a resolution of 
diarrhea in CDI and, if available, the proportion of 
patients free from relapse during the follow-up period, 
clinical remission and/or clinical improvement in UC and 
CD, and clinical improvement in pouchitis, constipation 
and IBS. In metabolic syndrome, clinical improvement 
after FMT was defined as the effect on peripheral 
insulin sensitivity. Secondary outcomes included: the 
proportion of patients who experienced any adverse 
event (AE), withdrawal due to adverse events, serious 
adverse events (SAE’s) (deaths or hospitalization) 
and adverse events potentially associated with fecal 
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transplantation including perforation, post-transplant 
sepsis or bacteremia, and transmission of communicable 
disease. 
Search strategy and selection criteria
We searched MEDLINE, EMBASE, and the Cochrane 
Library from inception to July 2013 using the search 
terms “feces”, “faeces”, “stool”, or “microbiota” 
combined with, “donor”, “donation”, “transplantation”, 
“therapy”, “infusion” or “bacteriotherapy” with assistance 
of a clinical librarian. Conference proceedings: European 
Crohn’s and Colitis Organization (ECCO 2009 to 2013); 
the United European Gastroenterology Week (UEGW 
2010 to 2013); the European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID 2012 to 
2013); the Infectious Diseases Society of America (IDSA 
2003 to 2012); Digestive Disease Week (DDW 1979 to 
2013); and the American College of Gastroenterology 
(ACG from 2010 to 2013) were searched to identify 
abstract publications. The search was limited to human 
subjects and English written articles. References from 
review articles were also searched to identify applicable 
studies that may have been missed by the database 
searches.
Data extraction
Records were imported into a bibliographic database 
and duplicates were removed manually. Where possible, 
those with potential overlaps in patient populations 
were identified before the analysis. In case of any 
uncertainty of duplicate data or where missing data 
were encountered, the author was contacted. Two 
authors (NGR and EMdV) independently assessed 
articles by title and abstract to determine eligibility. Full 
text articles were obtained for all studies deemed to be 
potentially eligible. Disagreements were resolved by 
discussion and consensus. The first author extracted 
data on the patient group (P), intervention (I), 
comparison (C) and outcome (O). Included studies 
were categorized according to indication for FMT. If 
patients received FMT for multiple indications [e.g., 
inflammatory bowel disease (IBD) and CDI] patients 
were categorized according to the condition for which 
the primary endpoint of the study was established.
Methodological quality of included studies
The Cochrane risk of bias tool was used to assess the 
methodological quality of the included RCT’s, each 
study was assessed for sequence generation, allocation 
concealment, blinding, handling of incomplete outcome 
data, selective outcome reporting and other sources 
of bias[15]. These items were rated as low (e.g., the 
study was double-blind and an identical placebo was 
used), high (e.g., study was open label), or unclear 
risk of bias (e.g., procedures for blinding were not 
adequately described). As no validated tool for the 
assessment of risk of bias in observational studies 
was available, we used the eight criteria for quality 
assessment of case series, published by Chambers et 
al[16]. These criteria address both quality of reporting 
as risk of bias. Each study was assessed for: adequate 
reporting of eligibility criteria, representative patient 
population, reporting measures of variability, reporting 
of loss to follow-up, follow-up of at least 90% of the 
included patients, prospective inclusion, consecutive 
recruiting of patients and relevant prognostic factors. 
These items were rated as “yes” or “no” resulting in an 
overall rating of “good”, if the answer was ‘‘yes’’ to all 
eight criteria; “satisfactory”, if the answer was ‘‘yes’’ to 
criteria 2, 4-7 and “poor”, if the answer was not ‘‘yes’’ 
to one or more of the criteria listed for ‘‘satisfactory.’’
Statistical analysis
The efficacy of treatment was compared across 
studies per treatment category. If more than one 
RCT was available per indication, a meta-analysis on 
efficacy of treatment was performed as appropriate. 
We intended to pool the data for meta-analyses if 
the patient groups, outcomes and interventions were 
sufficiently similar. This was determined by consensus. 
For case series, a summary of efficacy of treatment 
was reported. The overall treatment effect of FMT was 
calculated as the percentage of patients who received 
FMT and achieved clinical improvement per treatment 
category. All analyses were carried out on an intention-
to-treat (ITT) basis. As such, dropouts or withdrawals 
before the completion of the studies were considered 
to be treatment failures. If possible, the presence of 
heterogeneity among studies was assessed using the 
χ 2 test, the I2 statistic was used to assess the degree 
of inconsistency between the trials[17]. Sensitivity 
analyses were performed to investigate statistically 
significant heterogeneity. A sensitivity analysis was 
conducted to determine the impact of trial quality on 
the overall results. Trials deemed to be at high risk 
of bias were excluded from the analysis to see if the 
results changed. Efficacy of FMT was compared per 
route of administration (nasogastric or nasoduodenal 
tube infusion vs infusion into the colon vs retention 
enema). Data were analyzed using the SPSS statistics 
20 software.
RESULTS
Study selection
After duplicate removal, the search yielded 2029 
records. Based on screening of title and abstract 1817 
records were excluded, mainly because the topic did 
not pertain to FMT. For the remaining 212 records, 
reasons for exclusion are shown in Figure 1. Forty-five 
studies met the inclusion criteria and were included 
in the review. Only two RCTs were found, all other 
studies were retrospective series or pilot studies.
Risk of bias within studies
A quality assessment of included case series is 
presented in Table 1. Forty-two case series were rated 
as “poor”, only one of the included case series was 
5361 May 7, 2015|Volume 21|Issue 17|WJG|www.wjgnet.com
Rossen NG et al . Fecal microbiota transplantation as novel therapy
5362 May 7, 2015|Volume 21|Issue 17|WJG|www.wjgnet.com
and not routinely used in 1981[2,50]. Assessment of 
Clostridium toxin in the stool was not performed in all 
studies to confirm the diagnose CDI before treatment, 
nor to assess whether there was adequate clearance 
of CDI after treatment. Most of the studies measured 
clinical response with regard to patients’ symptoms. 
The diagnoses of IBD was confirmed by pathology 
in three studies[5,53,55], the other four studies did not 
confirm the diagnoses of IBD beyond clinical diagnoses 
by the treating physician[51,52,54,56]. Pinn et al[57] did not 
describe criteria for the diagnoses of IBS and included 
patients with diarrhea-predominant, constipation-
predominant and IBS patients with alternating stool 
pattern. Landy at al[9] confirmed chronic refractory 
pouchitis clinically, endoscopically and histologically. 
Borody et al[58] defined chronic constipation as a stool 
frequency of once every four to seven days associated 
with symptoms. Vrieze et al[10] used the following 
criteria for recruiting patients with a metabolic 
syndrome: a body mass index > 30 kg/m2 or waist 
circumference > 102 cm and a fasting plasma glucose 
level > 5.6 mmol/L. 
Follow-up varied between ten days to eight 
years in CDI, 12 wk to 16.5 years in IBD, six to 18 
mo in IBS, four weeks in pouchitis, one to 28 mo in 
constipation and six weeks in metabolic syndrome. Of 
the 45 included studies, two were randomised trials of 
FMT for CDI and metabolic syndrome, in which FMT 
was compared with active comparators or placebo 
respectively. van Nood et al[18] conducted an open-
label, RCT in patients with CDI in which the infusion 
of donor feces was preceded by a short regimen of 
vancomycin and bowel lavage, a standard vancomycin 
rated as “satisfactory”. None of the case series was 
considered to be of “good” quality. In 15 of the 43 case 
series, patients were prospectively included. Quality 
assessment of two included randomised studies is 
shown in Table 2. The study performed by Vrieze et 
al[10] was rated as high methodological quality on four 
out of five items, the study by van Nood et al[18] was 
rated as “high” methodological quality on three items. 
A sensitivity analysis to determine the impact of trial 
quality on the overall results could not be properly 
executed, due to the overall “poor” assessed quality of 
the included case series. Excluding the 32 case-series 
deemed to be at high risk of bias for sub-analyses of 
efficacy of fecal transplantation in CDI would result 
in determination of treatment effect in only one case 
series qualified as “satisfactory” compared to the only 
RCT included for this indication. In IBD, all included 7 
studies were assessed equally as “poor” quality, which 
made further comparison between studies impossible.
Patients, treatment information, and donor screening
The studies were published between 1958 and 2013. 
A total number of 1029 patients underwent FMT. The 
clinical efficacy of FMT was assessed in patients with: 
CDI[2,19-50] (n = 883), IBD[5,51-56] (n = 112), IBS[57] (n 
= 13), pouchitis[9] (n = 8), constipation[58] (n = 3) 
and metabolic syndrome[10] (n = 10 randomised to 
the donor feces arm). Age of the included patients 
varied widely from 6 to 94 years. Two studies on 
fecal transplantation in pseudomembranous colitis 
published in 1958 and 1981 were regarded as fitting 
the diagnoses of CDI although determination of 
Clostridium toxin was not available in the first study 
Records identified 
through EMBASE search 
n  = 1705
Records identified through 
MEDLINE search 
n  = 1059
Records identified through 
COCHRANE 
n  = 172
Records identified through 
other sources
n  = 54
Records after duplicates removal
n  = 2029
Article screened on basis of title and abstract
n  = 212
Included in analyses n  = 45
Clostridium difficile  34 
IBD 7
Constipation 1 
Metabolic syndrome 1 
Pouchitis 1
IBS 1
Records excluded (n  = 167) Based on
   Comment on article    26
   Article not in English language     5 
   Interview      4
   Full text could not be obtained   11
   Review or meta-analysis   62
   Opinion or expert panel   13
   Unclear definition of treatment    2
   Protocol       5
   Case report    21
   No clinical outcome      7
   Duplicate data    11
Figure 1  Identification, screening, eligibility and inclusion of studies. IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome.
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Table 1  Quality assessment of selected case series according to the Chambers criteria
Indication for 
FMT
Author Year Publication 
type (J, CA)
1 2 3 4 5 6 7 8 Case series quality 
rating
CDI Aas 2003 J + + + + + - - - Poor
Arkkila 2010 J - + + + + + - - Poor
Aroniadis 2013 J + - + + + - - - Poor
Bansal 2013 J - + - - ? - - - Poor
Bobo 2013 CA + - + + + + - - Poor
Borody 2013 CA - + + - ? - - - Poor
Bowden 1981 J - - + + + - - - Poor
Brandt 2012 J + + + + + - - - Poor
Byrne 2008 CA + + - - + + - - Poor
Eisman 1958 J - - - - - - - - Poor
Elopre 2013 J - - - - + - - - Poor
Fischer 2013 CA - - + + + - - + Poor
Garborg 2010 J + + - + + - - - Poor
Hamilton 2012 J + + + + + + + + Good
Ihunnah 2013 CA - - + + - - - - Poor
Jorup-Rönström 2012 J + + + + + - - - Poor
Kassam 2010 CA - + + + + + + - Satisfactory
Kelly 2012 J - + + + + - - - Poor
Khanna 2013 CA + + + - + + - - Poor
Louie 2013 CA + - - - - - - - Poor
MacConnachie 2009 J + + - - + - - - Poor
Mattila 2012 J + + + + + - - + Poor
Mellow 2010 J - + + + + - - - Poor
Miller 2010 J - + - - + - - - Poor
Neelakanta 2011 J - - - + + - - - Poor
Newton 2013 CA - - - - - - + - Poor
Potakamuri 2013 CA - + + - ? - - - Poor
Rohlke 2010 J - + - + + - - - Poor
Rubin 2013 J + + + + + - - - Poor
Shiekh Sroujieh 2012 CA + + + + + + - - Poor
Silverman 2010 J - + - - + - - - Poor
Yoon 2010 J + + + + + - - - Poor
Youngster 2013 CA + + - + + + - - Poor
IBD Angelberger 2012 J - + - + + + - - Poor
Borody 2012 CA - + +  +2  +2 - - - Poor
Greenberg 2013 CA - + +  -1  -1 - - + Poor
Kump 2013 CA - + - + + + - - Poor
Kump 2013 J + + + + + + - + Poor
Kunde 2013 J + + + + + + - +/- Poor
Vermeire 2012 CA - + + + + + - - Poor
IBS Pinn 2013 CA - - + - + - - - Poor
Pouchitis Landy 2013 CA + - + + + + - - Poor
Constipation Borody 2001 J - - - - + + - - Poor
1Sixteen out of 21 treated patients were successfully contacted for FU; 262 patients with FU results were included. Chambers criteria: (1) were selection/
eligibility criteria adequately reported? (2) was the selected population representative of that seen in normal practice? (3) was an appropriate measure of 
variability reported? (4) was loss to follow-up reported or explained? (5) were at least 90% of those included at baseline followed up? (6) were patients 
recruited prospectively? (7) were patients recruited consecutively? and (8) did the study report relevant prognostic factors? J: Journal article; CA: 
Conference abstract. ?: Unknown; CDI: Clostridium difficile-infection; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome.
Table 2  Methodological quality of included randomised trials
Ref. Random sequence 
generation
Allocation concealment Blinding Incomplete outcome 
data
Selective reporting
Vrieze et al[10] Low1 Unclear2 Low3 Low4 Low
van Nood et al[18] Low1 Unclear2 High3 Low Low
1Automated biased coin minimization, computer generated randomisation not in the paper but verified by the first author; 2Not described; rated as unclear 
for this item; 3Patients were randomised to either allogenic or autologous feces a, open label design; 4All patients completed the study; two subjects were 
excluded from analyses because of antibiotic use during the trial unrelated to the microbial infusion, all except one patient (due to a clinically driven 
protocol deviation) were taken into the intention to treat analyses.
Rossen NG et al . Fecal microbiota transplantation as novel therapy
5364 May 7, 2015|Volume 21|Issue 17|WJG|www.wjgnet.com
regimen, or a standard vancomycin regimen with 
bowel lavage. Vrieze et al[10] conducted a double-
blind placebo controlled trial, which compared the 
infusion of fecal intestinal microbiota from lean 
donors to autologous microbiota infusion in male 
recipients with metabolic syndrome. The remaining 
43 included studies were uncontrolled case series, 
in which patients were treated with FMT via the 
upper gastrointestinal tract (tube infusion via the 
stomach, duodenum or jejunum or oral ingestion of 
gelatin coated capsules containing microbes after 
centrifugation of a suspension of donor feces) or via 
the lower gastrointestinal tract or colon (infusion via 
the endoscope channel into the terminal ileum, coecum 
or sigmoid or rectal infusion by enema’s). Infusion via 
the upper GI route supposedly leads to more profound 
replacement of the microbiota in the small bowel and 
proximal colon. The mode of infusion for each study 
was categorized into administration via the upper GI 
tract (U), colon (C) or retention enema (Ce) Table 3. 
The amount of fresh feces prepared for infusion or the 
amount of infused fecal suspension was reported in 
23 studies and varied from 30 to 250 g of fresh stool, 
20 mL to 350 mL of fresh stool, 6 to 8 tablespoons of 
fresh stool in studies in which the amount of prepared 
feces per treatment was reported and 30 to 700 mL 
fecal infusion if the amount of infused suspension after 
adding saline solution was reported. FMT regiments 
varied between single treatments to 14-d regiments 
(Table 3). Different donors were used among studies; 
donors could be family friends, partners, relatives, 
friends or unrelated healthy subjects. Relation of the 
donor to the patient was expressed in 3 categories: 
“genetically related” (e.g., 1st or 2nd degree relative), 
“sharing the same household”; (e.g., partner) or 
“other” (e.g., healthy volunteer) (Table 3). Table 
4 shows the protocol for screening of fecal donors 
as used in the two RCT’s[10,18]. In 2013, already an 
optimized screening protocol for fecal donors was 
published by the same authors[59], which concerns not 
only the risk for transmission of infectious diseases, 
but also to the risk of transmitting other (autoimmune) 
diseases with regard to several conditions that may be 
transferred through feces.
Efficacy of FMT in CDI and IBD
CDI: In 33 case series published on CDI, the efficacy 
of FMT (defined as “resolution of diarrhea”) ranged 
from 87.8% to 90.0% in repeated FMT’s, comparable 
to a treatment effect of 81% to 94% in repeated 
FMT's in the single published RCT. Treatment efficacy 
> 80% was achieved in severe and complicated 
CDI[47], hospitalized patients[45], immunocompromised 
patients[26,41], patients with > 3 episodes of CDI in 
their medical history[32] and patients with underlying 
IBD[38,44]. Resolution of diarrhea and relapse-free 
FU (reported in 21 out of 34 studies) was 80.9% 
(range 46% to 100%). Number, age and gender of 
patients enrolled, additional clinical data on patient 
group, duration of follow-up, primary outcome and 
the percentage of included patients free from relapse 
during follow-up are shown in Table 5. 
IBD: Of patients treated with FMT for IBD, six patients 
were treated for CD and 106 for UC; four UC patients 
treated by Greenberg et al[56]. had concomitant CDI. 
All patients had active disease at inclusion varying 
from mild disease activity to therapy refractory 
disease. Location of IBD was reported in three out of 
seven studies. CD was located ileocolonic (n = 3) and 
restricted to the colon (n = 1) in the series published 
by Vermeire et al[55]. Extent of disease in UC was 
mostly a pancolitis[52,53]. Response to therapy was 
measured by five different assessments in UC: patient 
reporting of symptoms on a questionnaire comparing 
pre- and post-FMT data[56]; (clinical) Mayo score[53,60]; 
the total Mayo score[51]; the Paediatric UC Activity Index 
in children[52]; and the modified Powell-Tuck index[5]. In 
CD, two different clinical evaluation tools were used: 
“patient reporting of symptoms on a questionnaire 
comparing pre- and post-FMT data”[56] and the Crohn’s 
Disease Activity Index[55]. Five of the included studies 
used endoscopy for evaluation of mucosal response. 
Patients underwent endoscopy shortly after treatment 
(range 1 d to 90 d)[51,53,54], or on the longer term 
(1-198 mo, 34% of the patients were evaluated by 
endoscopy) in UC[5]. CD patients were evaluated by 
endoscopy eight weeks after FMT[55].
Clinical outcome data (measured by different 
standards) for FMT in IBD are shown in Table 6. In 
three of six studies on UC in which clinical remission 
was reported the percentage of patients who achieved 
clinical remission varied between 0% and 68%[5,52,53]. 
Clinical improvement was reported in six studies and 
varied between 20% and 92%[5,51-54,56]. 
In CD, the four patients treated by Vermeire et 
al[55] did not experience clinical improvement after FMT. 
Greenberg et al[56] reported “improved frequency of 
disease flares” in 63% of the patients; combined for 
both UC and CD, results for “improvement of diarrhea” 
were reported separately, and one out of two treated 
CD patients reported a decrease in diarrhea frequency. 
In the four CD patients in whom an endoscopy was 
performed 8 wk after treatment, no endoscopic benefit 
was observed[55]. 
FMT in other indications
In total, three patients were treated for chronic 
constipation as part of a case series on FMT in both 
chronic constipation and UC[58]. In 100% of the 
patients there was complete reversal of constipation; 
defecation occurred one to two times per day without 
laxatives with an accompanying resolution of most 
associated symptoms such as episodic nausea and 
vomiting, bloating and abdominal pain, after FMT. 
Pinn et al[57] treated 13 IBS patients, resolution or 
Rossen NG et al . Fecal microbiota transplantation as novel therapy
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Additional analyses
In CDI patients, the proportion of patients who 
achieved resolution of diarrhea after administration 
of FMT via the upper GI tract: 84.2% (n = 150), into 
the colon: 89.4% (n = 326) and per retention enema: 
88.5% (n = 102) was comparable, P = 0.26. In the 
majority of UC patients (72%), mode of administration 
of FMT was not reported. In CD, not from all six 
patients the route of administration was reported and 
a comparison of efficacy of treatment according to 
Table 4  Donor screening for fecal microbiota transplantation
Screening questionnaire1
   A questionnaire addressing risk factors for potentially transmissible diseases
Fecal test
   Parasites, including Blastocystis hominis and Dientamoeba fragilis
   Clostridium difficile, and enteropathogenic bacteria
Serology
   Antibodies to HIV, human T-cell lymphotropic virus types 1 and 2, hepatitis A, B, and C, Cytomegalovirus, Epstein-Barr virus
   Treponema pallidum, Strongyloides stercoralis, and Entamoeba histolytica
1Screening according to van Nood et al[18] and Vrieze et al[10].
Table 5  Studies on fecal microbiota transplantation in Clostridium difficile -infection, outcome data
First author Year Patients 
enrolled 
(n)
Age (mean ± SD or 
median, range/IQR)
Male sex 
(n)
FU Primary 
endpoint
Resolution of 
diarrhea
Resolution of diarrhea + 
free from relapse during 
FU
Aas 2003  181 73 ± 9   5 3 mo 90 d   94% \
Arkkila 2010 37 69 (24-90) 12 mo   92%   86%
Aroniadis 2013  132 70 (38-89)   3 15 mo (1-42) 1-7 d 84%, 92%3   50%
Bansal 2013 12 70 (31-96)   4 3 mo > 90 d   92% \
Bobo 2013  214 70.9 ± 11.9 10 1 mo 30 d   95% \
Borody 2013  285 F:36 ± 18.1 M: 31 ± 16 17   86%
Bowden 1981 16 56 (14-85)   7 12 d 12 d   81% \
Brandt 2012 77 65 ± 17 21 17 mo (3-68) 90 d   91%   81%
Byrne 2008 45 62 (30-91) 12 12 mo   96%
Eisman 1958   4 45-68   3 < 10 d 24-48 h 100% 100%
Elopre 2013    26 48, 48   1 5 yr and 6 wk 1 d 100% 100%
Fischer 2013  127 46 ± 17   7 30 d 7 d 75%/, 92%/3   75%
Garborg 2010 39 75 (53-94) 18 3 mo 80 d 73%, 83%3 \
Hamilton 2012  435 69 ± 21 12 2 mo 1-2 mo 86%, 95%3
Ihunnah 2013  668 12 mo (3-51) 78%, 89%3 78% after 12 wk
Jorup-Rönström 2012 32    75 (27–94) 12 26 mo (1-68)   69%
Kassam 2010  141 65.3 (26-87)   7 7 mo 24 h 100%
Kelly 2012 26    59 (19-86)   2 11 mo (2-30) post FMT   92%   85%
Khanna 2013  135    27 (21-48)   8 1-14 d   50%
Louie 2013  259 6 mo 100% 100%
MacConnachie 2009  151 81.5 (68-95) 14 4 mo (1-6) 5-24 wk 73%, 80%3   67%
Mattila 2012  701    70 (22-90) 28 12 mo 12 wk   94%   89%
Mellow 2010  131    67 (32-87)   7 5 mo (1-10) 30 d   92%   85%
Miller 2010   2 34-50   0 9 mo, 1 mo 9 mo, 1 mo 100% \
Neelakanta 2011    25 27-39   1 12 mo, 5 mo 2 wk, post FMT   50%   50%
Newton 2013  176 90 d post FMT   94%   76%
Potakamuri 2013 13 73.8 ± 18.8   2 5 wk- 18 mo > 1 mo   92%   46%
Rohlke 2010 19   49 (29-82)   2 27.2 yr (6-65) 6 mo 95%, 100%3   79%
Rubin 2013    741,8 63 (6-94) 26 2 mo 60 d   79%   58%
Shiekh Sroujieh 2012 68   66 (16-93) 100 d 1-4 d 100% 100%
Silverman 2010   7   72 (30-88)   4 4- 14 mo post FMT 100% 100%
Van Nood 2013     161,10 73 ± 13   8 2.5- 5 mo 10 wk 81%, 94%3   81%
Yoon 2010 12   66 (30-86)   3 3 wk- 8 yr 3-5 d 100% 100%
Youngster 2013 12 2 mo 8 wk   92% \
1Recurrent/refractory CDI. Aas et al (18), Kassam et al (7), MacConnachie et al (15), Mattila et al (70), Mellow et al (13), Rubin et al (74), van Nood et al 
(16); 2Severe CDI 84%, complicated CDI 92%; 3Resolution of diarrhea (% of the patients) after 2 FMT's; 4All patients were hospitalised at inclusion; 5IBD. 
Hamilt et al (14): CD (6), UC (4), lymphocytic colitis (4). Neelak et al (1 UC, 1 CD). Khanna et al CD (7), UC (6). Borody et al CD (14), UC (14); 6Patients 
were immunocompromised: upon review of their medical history, Newton et al (7) based on HIV Elopre et al (2); 7Other diagnoses (12): UC (3), UC and 
livertransplant for PSC (1), CD(3), multivisceral transplant (2), multiple myeloma (1), lung transplant (1), renal transplant (1); 8Cases included 5 pediatric 
(Ihunnah et al) and 2 pediatric patients (Rubin et al); 9> 3 episodes (25); 10Amount of patients randomised to intervention (FMT) arm. /: Outcome defined 
as negative stool test (PCR) after FMT only; \: No further follow up after archivieving the primary endpoint. FMT: Fecal microbiota transplantation; FU: 
Follow-up.
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infusion for adequate position in the duodenum, 
aspiration of fecal contents does not constitute a 
problem. Furthermore, we have not encountered 
transmission of microbial pathogens. In our opinion, 
FMT could be incorporated in clinical practice for CDI if 
there is adequate in house facilities. Currently, patients 
with IBD should only be treated in clinical trials, since 
there is a paucity of evidence in these patients.
The evidence for FMT in this systematic review 
is mostly based on case series of poor quality, with 
the exception of two RCT’s in CDI and metabolic 
syndrome, both from our own institution. Worldwide, 
FMT became quickly part of clinical care rather than 
an experimental treatment in series on CDI and IBD. 
Follow-up data were retrospectively collected in a 
selection of patients up to 16.5 years after treatment in 
65% of the included series, which could have resulted 
in publication and selection bias. After agreement 
with the authors, four studies were excluded because 
of duplicate data (overlap of conference proceedings 
and corresponding full publication or overlap between 
patient populations)[58,61-63]. In four articles, the first 
authors could not confirm overlap between patient 
populations and we choose not to exclude these studies, 
which could have led to over- or underestimation of 
primary and secondary outcome data presented in this 
review[24,29,37,43]. The strength of our study also harbors 
its limitation. By including conference proceedings 
we strived to collect all available data on this novel 
treatment modality. However these abstract reports 
were brief and lacked details on the methods used for 
screening and FMT treatment. This approach bears the 
risk of reporting on studies that have not gone through 
the process of peer review.
More robust data on FMT will become available 
in the next two to three years. Currently, there are 
12 trials on IBD; seven on UC, two on CD and three 
on IBD in general, and ten trials on CDI registered 
on clinical trials.gov. Fifteen of these studies are 
randomized trials. Single studies are registered for 
metabolic syndrome, IBS, pouchitis and healthy 
volunteers examining the restoration of the patient’
s fecal microbiota after antimicrobial exposure. All of 
these trials will give rise to new research questions 
including preferred route of administration, and the 
number of FMT’s needed to attain remission or cure. In 
addition, by using FMT as a highly informative human 
model of the interaction between the gut microbiome 
and the host, a wealth of data will be generated 
regarding the pathophysiology of several diseases.
In conclusion, FMT appears to be highly effective in 
Clostridium difficile-infection and may be a promising 
therapy in ulcerative colitis. Infusion of donor feces 
significantly increased insulin sensitivity in male patients 
with a metabolic syndrome. As for Crohn’s disease, 
chronic constipation, pouchtis and IBS data are still 
too limited to draw conclusions. FMT is performed 
according to not yet standardized treatment protocols 
and despite the absence of infectious complications 
in 1029 patients reported in this review, vigilant 
surveillance of adverse events is needed. More 
randomized controlled data on the long-term efficacy 
of FMT as well as translational data on the impact of 
modulating the patient’s microbiota by the infusion of 
donor feces and all its contents are still warranted. 
COMMENTS
Background
Fecal Microbiota transplantation (FMT) was first reported in the literature in 
1958. Since that time, approximately 500 patients who received FMT were 
reported in the literature for different indications: infectious diarrhea [Clostridium 
difficile-infection (CDI)], gastro-intestinal diseases [inflammatory bowel disease 
(IBD), irritable bowel syndrome (IBS), pouchitis, constipation) and Metabolic 
Syndrome. The majority these patients received FMT for CDI, which was 
proven as a more effective therapy when compared to treatment with antibiotics 
in a randomized controlled trial. FMT is widely used as clinical therapy for a 
wide range of indications whereas the available evidence in the literature is 
scarce. 
Research frontiers
In order to accurately assess the application of FMT, the authors systematically 
reviewed the clinical efficacy and safety of FMT in different indications. 
Innovations and breakthroughs
FMT is highly effective in CDI, and holds promise in ulcerative colitis. As for 
Crohn’s disease, chronic constipation, pouchitis and IBS data are too limited 
to draw conclusions. FMT increases insulin sensitivity in metabolic syndrome. 
Based on the current results, FMT can be considered as a safe treatment in the 
studied population. 
Applications
Vigilant surveillance of adverse events is needed, since FMT is performed 
according to not yet standardized treatment protocols. More randomized 
controlled data on the long-term efficacy of FMT as well as translational data on 
the impact of modulating the patient’s microbiota by the infusion of donor feces 
and all its contents are still warranted.
Peer-review
This paper reviewed the clinical efficacy and safety of FMT on CDI, 
inflammatory bowel disease, metabolic syndrome, constipation, pouchitis 
and IBS. Promising results were obtained and further studies are needed to 
elucidate the mechanisms of FMT and to guard the adverse effects in large 
population of the patients. 
REFERENCES
1 Ge H. Zhou Hou Bei Ji Fang. tianjin: tianjin Science and 
technology, 2000
2 Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as 
an adjunct in the treatment of pseudomembranous enterocolitis. 
Surgery 1958; 44: 854-859 [PMID: 13592638 DOI: 10.1067/
S0039-6060(03)00474-4]
3 Schwan A, Sjölin S, trottestam U, Aronsson B. Relapsing 
Clostridium difﬁcile enterocolitis cured by rectal infusion of normal 
faeces. Scand J Infect Dis 1984; 16: 211-215 [PMID: 6740251]
4 Bennet JD, Brinkman M. treatment of ulcerative colitis by 
implantation of normal colonic flora. Lancet 1989; 1: 164 [PMID: 
2563083 DOI: 10.1016/S0140-6736(89)91183-5]
5 Borody T, Wettstein A, Campbell J, Leis S, torres M, Finlayson 
S, Nowak A. Fecal microbiota transplantation in ulcerative colitis: 
Review of 24 years experience. Am J Gastroenterol Conf 77th Annu 
Sci Meet Am Coll Gastroenterol 2012; 107: S665 [DOI: 10.1038/
ajg.2012.275]
6 Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, 
Hyland L, Morgan A, Maysey J, Moore-Jones D. Bowel-flora 
alteration: a potential cure for inflammatory bowel disease and 
irritable bowel syndrome? Med J Aust 1989; 150: 604 [PMID: 
2783214]
7 Andrews PJ, Barnes P, Borody tJ. Chronic constipation reversed 
 COMMENTS
Rossen NG et al . Fecal microbiota transplantation as novel therapy
5370 May 7, 2015|Volume 21|Issue 17|WJG|www.wjgnet.com
by restoration of bowel flora: A case and a hypothesis. Eur J 
Gastroenterol Hepatol 1992; 4: 245-247
8 Grehan MJ, Borody tJ, Leis SM, Campbell J, Mitchell H, Wettstein 
A. Durable alteration of the colonic microbiota by the administration 
of donor fecal flora. J Clin Gastroenterol 2010; 44: 551-561 [PMID: 
20716985 DOI: 10.1097/MCG.0b013e3181e5d06b]
9 Landy J, Omar Al-Hassi H, Ronde E, Mann E, Peake S, 
McLaughlin S, Perry-Woodford ZL, Ciclitira PJ, Nicholls RJ, Clark 
SK, Knight S, Hart AL. A prospective controlled pilot study of faecal 
microbiota transplantation for chronic refractory pouchitis. ECCO 
Conf Abstr 2013; P591
10 Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, 
Bartelsman JF, Dallinga-thie GM, Ackermans Mt, Serlie MJ, 
Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks 
VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos 
WM, Hoekstra JB, Nieuwdorp M. transfer of intestinal microbiota 
from lean donors increases insulin sensitivity in individuals with 
metabolic syndrome. Gastroenterology 2012; 143: 913-916.e7 
[PMID: 22728514 DOI: 10.1053/j.gastro.2012.06.031]
11 Borody TJ, Nowak A, torres M, Campbell J, Finlayson S LS. 
Bacteriotherapy in chronic fatigue syndrome (CFS): a retrospective 
review. Am J Gastroenterol 2012; 107: 1481
12 Borody TJ, Campbell J, torres M, Nowak A, Leis S. Reversal 
of idiopathic thrombocytopenic purpura with Fecal Microbiota 
transplantation (FMt). Am J Gastroenterol 2011; 106: 941
13 Borody TJ, Leis S, Campbell J, torres M, Nowak A, Fecal 
microbiota transplantation (FMt) in multiple sclerosis (MS). Am J 
Gastroenterol 2011; 942
14 Liberati A, Altman DG, tetzlaff J, Mulrow C, Gøtzsche PC, 
Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. 
the PRISMA statement for reporting systematic reviews and 
meta-analyses of studies that evaluate health care interventions: 
explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34 
[PMID: 19631507]
15 Higgins JPT, Altman DG. Assessing risk of bias in included 
studies. In: Higgins JPt, Green S, editors. Cochrane Handbook for 
Systematic Reviews of Interventions: Cochrane Book Series. Version 
510 (updated March 2011), Cochrane Collab 2011. Available from: 
URL: http://www.cochrane-handbook.org
16 Chambers D, Rodgers M, Woolacott N. Not only randomized 
controlled trials, but also case series should be considered in 
systematic reviews of rapidly developing technologies. J Clin 
Epidemiol 2009; 62: 1253-1260.e4 [PMID: 19349144 DOI: 10.1016/
j.jclinepi.2008.12.010]
17 Higgins JP, thompson SG, Deeks JJ, Altman DG. Measuring 
inconsistency in meta-analyses. BMJ 2003; 327: 557-560 [PMID: 
12958120 DOI: 10.1136/bmj.327.7414.557]
18 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, 
de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, tijssen JG, 
Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor 
feces for recurrent Clostridium difﬁcile. N Engl J Med 2013; 368: 
407-415 [PMID: 23323867 DOI: 10.1056/NEJMoa1205037]
19 Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, 
Alm EJ, Gevers D, Russell GH, Hohmann EL. Fecal microbiota 
transplant for relapsing Clostridium difficile infection using a 
frozen inoculum from unrelated donors: a randomized, open-label, 
controlled pilot study. Clin Infect Dis 2014; 58: 1515-1522 [PMID: 
24762631]
20 Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difﬁcile-
associated disease by donated stool transplanted via colonoscopy: 
a case series of 12 patients. J Clin Gastroenterol 2010; 44: 562-566 
[PMID: 20463588 DOI: 10.1097/MCG.0b013e3181dac035]
21 Silverman MS, Davis I, Pillai DR. Success of self-administered 
home fecal transplantation for chronic Clostridium difﬁcile infection. 
Clin Gastroenterol Hepatol 2010; 8: 471-473 [PMID: 20117243 
DOI: 10.1016/j.cgh.2010.01.007]
22 Shiekh Sroujieh L, Hassan M, Zainah H, Alangaden G, Jeepalyam 
S, Morilla Holguin ME, Johnson L, Zervos M, Ramesh M. Intestinal 
Microbiota transplantation (Fecal transplantation) for Clostridium 
difﬁcile Infection-A Single Center Experience. ID week 1223 2012
23 Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome 
transplantation for recurrent Clostridium difficile infection: report 
on a case series. Anaerobe 2013; 19: 22-26 [PMID: 23182843 DOI: 
10.1016/j.anaerobe.2012.11.004]
24 Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for 
recurrent Clostridium difficile infection: results and methodology. 
J Clin Gastroenterol 2010; 44: 567-570 [PMID: 20485184 DOI: 
10.1097/MCG.0b013e3181dadb10]
25 Potakamuri Lakshmi N, turnbough L, Maheshwari A, Kantsevoy 
S, Ofosu A, thuluvath PJ. Effectiveness of Fecal Microbiota 
Transplantation for the treatment of recurrent Clostridium difﬁcile 
infection: Community hospital experience. ACG Annu Sci Meet 
Abstr 2013; P933
26 Newton D. Fecal Biotherapy as treatment for recurrent Clostridium 
difﬁcile infection in immunocompromised patients. ACG Annu Sci 
Meet Abstr 2013; P925
27 Neelakanta A, Moudgal V, Upadhyay N, Valenstein P, Gunaratnam 
Nt. Successful treatment of Refractory Clostridium difficile 
Infection(Cdi) With Intestinal Microbiota transplant (IMt) in 
two Patients With Inflammatory Bowel Disease (IBD) and Its 
Effects on IBD. Gastroenterology 2011; 142: S-395 [DOI: 10.1016/
S0016-5085(12)61499-1]
28 Miller CB, Dellon E, Isaacs K, Gangarosa L. Fecal bacteriotherapy 
via colonoscopy as rescue therapy for refractory and recurrent 
clostridium difﬁcile - Associated diarrhea. Am J Gastroenterol 2010; 
105: S323
29 Mellow M. Colonoscopic fecal bacteriotherapy in the treatment of 
recurrent clostridium difﬁcile infection-results and follow-up. Am J 
Gastroenterol 2010; 105: 121-150
30 Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, 
Ristikankare M, Moilanen V, Salminen K, Seppälä M, Mattila PS, 
Anttila VJ, Arkkila P. Fecal transplantation, through colonoscopy, 
is effective therapy for recurrent Clostridium difficile infection. 
Gastroenterology 2012; 142: 490-496 [PMID: 22155369 DOI: 
10.1053/j.gastro.2011.11.037]
31 MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal 
transplant for recurrent Clostridium difﬁcile-associated diarrhoea: a 
UK case series. QJM 2009; 102: 781-784 [PMID: 19726581 DOI: 
10.1093/qjmed/hcp118]
32 Louie T, Cannon K, O’Grady H, Wu K, Ward L. Fecal microbiome 
transplantation (FMt) via oral fecal microbial capsules for recurrent 
Clostridium difﬁcile infection (rCDI). ID week 2013
33 Khanna S, Kashyap PC, Rainey JF, Kammer PP, Loftus EV. 
Outcomes from Fecal Microbiota trasplantation in adults with C. 
difﬁcile Infection and Inflammatory Bowel Disease. ACG Annu Sci 
Meet Abstr 2013; 1657
34 Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation 
for relapsing Clostridium difficile infection in 26 patients: 
methodology and results. J Clin Gastroenterol 2012; 46: 145-149 
[PMID: 22157239 DOI: 10.1097/MCG.0b013e318234570b]
35 Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplantation 
via Retention Enema is Effective for Recurrent or Refractory 
Clostridium difﬁcile-Associated Diarrhea. Gastroenterology 2010; 
138: S207-S208 [DOI: 10.1016/S0016-5085(10)60939-0]
36 Jorup-Rönström C, Håkanson A, Sandell S, Edvinsson O, 
Midtvedt t, Persson AK, Norin E. Fecal transplant against relapsing 
Clostridium difficile-associated diarrhea in 32 patients. Scand J 
Gastroenterol 2012; 47: 548-552 [PMID: 22468996 DOI: 10.3109/0
0365521.2012.672587]
37 Ihunnah C, Khoruts A, Fischer M, Afzali A, Aroniadis, Barto A, 
Borody tJ, Brandt LJ, Giovanelli A, Gordon S, Hohmann E, Kao D, 
Kao J, McQuillen DP, Mellow M, Rank K, Arnab R, Schwartz M, 
Singh N, Stollman N, Surawicz C, Suskind D, Vindigni S, Youngster 
I, Kelly C. Fecal Microbiota transplantation (FMt) for treatment 
of Clostridium difficile Infection (CDI) in Immunocompromised 
Patients. ACG Annu Sci Meet Abstr 2013; S179-S180
38 Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. 
Standardized frozen preparation for transplantation of fecal 
microbiota for recurrent Clostridium difficile infection. Am J 
Gastroenterol 2012; 107: 761-767 [PMID: 22290405 DOI: 10.1038/
Rossen NG et al . Fecal microbiota transplantation as novel therapy
5371 May 7, 2015|Volume 21|Issue 17|WJG|www.wjgnet.com
ajg.2011.482]
39 Garborg K, Waagsbø B, Stallemo A, Matre J, Sundøy A. Results of 
faecal donor instillation therapy for recurrent Clostridium difﬁcile-
associated diarrhoea. Scand J Infect Dis 2010; 42: 857-861 [PMID: 
20662620 DOI: 10.3109/00365548.2010.499541]
40 Fischer M. Fecal MIcrobiota transplantation for recurrent 
Clostridium difﬁcile in patients with prolonged immunosuppression. 
UEGW 2013; P922
41 Elopre L, Rodriguez M. Fecal microbiota therapy for recurrent 
Clostridium difﬁcile infection in HIV-infected persons. Ann Intern 
Med 2013; 158: 779-780 [PMID: 23689775]
42 Byrne B, Ward L, Louie M, Louie t, Krulicki WA, Louie tJ. Home-
Based Fecal Flora Infusion to Arrest Multiply-Recurrent Clostridium 
difficile Infection(CDI). ID week k-4201 abstract 2008. ID week 
2008
43 Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park 
t, Stollman N, Rohlke F, Surawicz C. Long-term follow-up of 
colonoscopic fecal microbiota transplant for recurrent Clostridium 
difﬁcile infection. Am J Gastroenterol 2012; 107: 1079-1087 [PMID: 
22450732 DOI: 10.1038/ajg.2012.60]
44 Borody TJ, Wettstein A, Nowak S, Finlayson SL. Fecal Microbiota 
transplantation (FMt) eradicated clostridium difficile infection 
(CDI) in inflammatory bowel disease (IBD). UEGW 2013
45 Bobo L. Fecal Microbial transplantation: Highly Effective 
Treatment for Severe Clostridium difﬁcile Infection. ID week 2013; 
281-284 [DOI: 10.4135/9781412964623.n89]
46 Siddharth B, Serban R, Kemal NR, Casey K, Dunnigan K. Fecal 
Microbiota Transplant for recurrent Clostridium difﬁcile infection at 
a teaching hospital in upstate New York our experience. ACG Annu 
Sci Meet Abstr 2013; P976
47 Aroniadis OC, Brandt LJ, Greenberg A, Borody tJ, Mellow M, 
Surawicz C, Cagle LA, Neshatian L. Long-term Follow-up Study of 
Fecal Microbiota transplantation (FMt) for Severe or Complicated 
Clostridium difﬁcile Infection (CDI). Gastroenterology 2013; 144: 
S185 [DOI: 10.1016/S0016-5085(13)60656-3]
48 Arkkila PE, Uusitalo-Seppälä R, Lehtola L, Moilanen V, 
Ristikankare M, Mattila EJ. Fecal Bacteriotherapy for Recurrent 
Clostridium difficile Infection. Gastroenterology 2010; 138: S-5 
[DOI: 10.1016/S0016-5085(10)60023-6]
49 Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile 
colitis: case series involving 18 patients treated with donor stool 
administered via a nasogastric tube. Clin Infect Dis 2003; 36: 
580-585 [PMID: 12594638 DOI: 10.1086/367657]
50 Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous 
enterocolitis: mechanism for restoring floral homeostasis. Am Surg 
1981; 47: 178-183 [PMID: 7224366]
51 Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, 
Dejaco C, Papay P, Novacek G, trauner M, Loy A, Berry D. 
temporal bacterial community dynamics vary among ulcerative 
colitis patients after fecal microbiota transplantation. Am J 
Gastroenterol 2013; 108: 1620-1630 [PMID: 24060759 DOI: 
10.1038/ajg.2013.257]
52 Kunde S, Pham A, Bonczyk S, Crumb t, Duba M, Conrad H, 
Cloney D, Kugathasan S. Safety, tolerability, and clinical response 
after fecal transplantation in children and young adults with 
ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56: 597-601 
[PMID: 23542823 DOI: 10.1097/MPG.0b013e318292fa0d]
53 Kump PK, Gröchenig HP, Lackner S, trajanoski S, Reicht G, 
Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs 
GJ, Gorkiewicz G, Högenauer C. Alteration of intestinal dysbiosis 
by fecal microbiota transplantation does not induce remission 
in patients with chronic active ulcerative colitis. Inflamm Bowel 
Dis 2013; 19: 2155-2165 [PMID: 23899544 DOI: 10.1097/
MIB.0b013e31829ea325]
54 Kump PK, Gröchenig HP, Spindelböck W, Gorkiewicz G, Wenzl 
H, Petritsch W, Reicht G. Preliminary clinivcal results of repeatedly 
fecal microbiota transplantation (FMt) in chronic activ ulcerative 
colitis. UEGW 2013; OP187
55 Vermeire S, Joossens M, Verbeke K, Hildebrand F, Machiels K, 
Van den Broeck K, Van Assche G, Paul J. Rutgeerts, Jeroen Raes2 
3. Pilot Study on the Safety and Efficacy of Faecal Microbiota 
transplantation in Refractory Crohn. Gastroenterology 2012; 142: 
P7160, S-360
56 Greenberg A, Aroniadis O, Shelton C, Brandt LJ. Long-term follow-
up study of fecal microbiota transplantation (FMT) for Inflammatory 
Bowel Disease (IBD). ACG Annu Sci Meet Abstr 2013; P1629
57 Pinn D, Aroniadis O, Brandt LJ. Follow-up study of fecal microbiota 
transplantation (FMt) for the treatment of refractory irritable bowel 
synrome (IBS). ACG Annu Sci Meet Abstr 2013; P1688
58 Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. 
Bacteriotherapy using fecal flora: toying with human motions. J Clin 
Gastroenterol 2004; 38: 475-483 [PMID: 15220681]
59 Vrieze A, de Groot PF, Kootte RS, Knaapen M, van Nood E, 
Nieuwdorp M. Fecal transplant: a safe and sustainable clinical 
therapy for restoring intestinal microbial balance in human disease? 
Best Pract Res Clin Gastroenterol 2013; 27: 127-137 [PMID: 
23768558 DOI: 10.1016/j.bpg.2013.03.003]
60 Kump PK, Gröchenig HP, Lackner S, trajanovski S, Reicht G, 
Hoffmann, Wenzl HH, Petritsch W, Gorkiewicz G. Successful 
improvement of dysbiosis by fecal microbiota transplantation is not 
sufficient to induce clinical remission in chronic active ulcerative 
colitis. ECCO 2013; P364
61 Borody TJ, Warren EF, Leis S, Surace R, Ashman O. treatment of 
ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 
2003; 37: 42-47 [PMID: 12811208 DOI: 10.1097/00004836-200307
000-00012]
62 Kelly C. Successful treatment of recurrent clostridium difficile 
infection with donor stool administered at colonoscopy: A case 
series. Am J Gastroenterol 2010; S135
63 Angelberger S, Lichtenberger C, Gratzer C, Papay P, Primas C, 
Eser A, Mikulits A, Dejaco C, Novacek G, Vogelsang H, Reinisch W. 
Fecal transplantation in patients with moderately to severely chronic 
active ulcerative colitis (UC). J Crohn’s Colitis 2012; 6: S159 [DOI: 
10.1016/S1873-9946(12)60393-6]
P- Reviewer: Adler MG, Carter D, Li SD    S- Editor: Ma YJ 
L- Editor: A    E- Editor: Wang CH 
Rossen NG et al . Fecal microbiota transplantation as novel therapy
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
1  7
